One test, ten cancers, unlimited possibilities – should be a big hit!

One test, ten cancers, unlimited possibilities. A new way to screen for many cancers all in one go should be a big hit.

StageZero Life Sciences Ltd. (TSX: SZLS) is dedicated to the early detection of cancer and multiple disease states through whole blood examination. StageZero’s next-generation test, Aristotle® is a panel for simultaneously screening for 10 cancers from a single sample of blood.

StageZero – Ten cancers detected from just one test

Aristotle is been built on a proprietary mRNA technology platform, which has been validated in more than 10,000 patients for the development of the first liquid biopsy for colorectal cancer. ​For years the healthcare community has been waiting for a test that can find ovarian and other cancers early. That wait is now over.

StageZero’s Prostate Health Index

This past September was prostate cancer awareness month and StageZero participated in a direct consumer marketing campaign awareness program. There are over 3 million men living with prostate cancer in the U.S. with 1 in 9 men being diagnosed in their lifetimes. Deploying both paid organic search and social media campaigns, the program was designed to create awareness for the Prostate Health Index. Approved by the FDA the Prostate Health Index is a blood test that can help differentiate prostate cancer from benign conditions in men with elevated PSA that will help both patients and their physicians decide if a prostate biopsy is indicated.

James-Howard-Tripp, CEO of StageZero Life Sciences states: “We were delighted to see the amount of interest this generated in such a short period of time.”

The campaign featured a select number of Facebook and Google ads targeting patients looking for more information on prostate cancer and prostate health. During the September period, StageZero inspired the interest of over 150,000 people searching for more information on prostate cancer resulting in more than 6,700 prospective patients hyper-linking through to the companies landing pages (2.6% Facebook and 8.5% Google ads compared to the industry average of 2.5%).

StageZero CEO James-Howard-Tripp continues: “This is exciting. We are engaging directly with a large number of consumers for the first time and helping to educate and empower patients who fall into the diagnostic gap of prostate cancer screening.”

StageZero is in the process of contacting potential patients who asked about having the test done. Those that completed the intake form will have their information reviewed in a HIPAA compliant portal by a qualified physician. From there, patients will be invited to proceed with the $299 Prostate Health Index test. This includes the telehealth physician consult/prescription and the blood draw at one of the Company’s national draw sites.

StageZero Life Sciences partners with Coastal Medical

To increase the Company’s reach to physician practices, StageZero is also partnering with Coastal Medical, a privately held sales organization in Savannah, Georgia. This regional sales organization specializes in selling advanced diagnostic testing solutions throughout the Southeast where initial efforts will be concentrated on selling StageZero testing in Atlanta and South Carolina.

Coastal Medical has relationships with primary care practices in the region as well as having inroads into some of the larger hospital systems in the Southeast.

Coastal Medical’s CEO Paul Ewaldsen comments: “We are fully committed to helping physicians incorporate early cancer detection programs into their practice. We believe that StageZero offers a unique testing program and advanced diagnostics that address non-compliant patients and gaps in current screening methods.”

StageZero is detecting early stage cancer

Headquartered in Richmond Hill, ON Canada; StageZero Life Sciences believes their proprietary blood testing could change the lives of the whole planet. The Company has a market cap of just C$ 16.65 million.

James Hunter on destigmatizing wealth management for our Baby Boomers

“We are seeing an aging population. Around 40% of individuals over the age of 65 experience some sort of memory loss. So, it is going to become more of an issue especially where wealth management is concerned and the dynamics of the advisor-client relationship…”, States James Hunter, Head of Wealth Management at Echelon Wealth Partners Inc., in an interview with InvestorIntel’s Tracy Weslosky.

James went on to say that older adults should have a plan ready for any financial uncertainty and a good advisor can help with that. He said that Echelon advisors are equipped with this advice. They can give advice around seeking power of attorney and advice in terms of who to appoint as the power of attorney. Echelon can make sure that a client’s documents are in a centralized safe location that family members and trusted individuals are aware of where those documents are.

To access the complete interview, click here


Dobbin on Nova Leap Health’s 8th consecutive quarter of record revenue growth

“It was a great quarter for us. We have been producing quarter-over-quarter record results. We have record revenue, record gross margin, record EBITDA. We have been producing record operating cash flow. So it has been fantastic last several quarters and it is our eighth consecutive quarter of record revenue growth.”, States Chris Dobbin, President and CEO of Nova Leap Health Corp. (TSXV: NLH), in an interview with InvestorIntel’s Tracy Weslosky.

Chris went on to say that Nova Leap identified very early on that there was a very fragmented market in the home care space. The company has been acquiring very small owner-operated home care companies and now it is seeing very strong organic growth along with continued successful acquisitions. Chris also said that Nova Leap was recently ranked number 4 on the 2019 Canadian Business and Maclean’s Startup 50 ranking of Canada’s Top New Growth Companies.

To access the complete interview, click here

Disclaimer: Nova Leap Health Corp. is an advertorial member of InvestorIntel Corp.

SOL Global has a new name Bluma Wellness Inc., and a new focus to become profitable

SOL Global Investments Corp. (CSE: SOL) will be having a special meeting of common shareholders on October 15, 2019 where they will be asked to consider and approve the proposed change of business from an international cannabis investment company, to that of a U.S. multi-state cannabis operator (MSO) under the Life Sciences category of the Canadian Securities Exchange (CSE). In connection with the Company’s proposed change of business shareholders will also be asked to consider and approve a change of name of the Company to “Bluma Wellness Inc.”.

SOL Investment Group (SIG) will be spun out of SOL Global and operate completely independent of Bluma Wellness and HeavenlyRx. SOL Global intends to spin off all of SOL Global’s non-multi-state cannabis operator (MSO) assets not under the Bluma Wellness umbrella to SIG. Further details of the spin-off transaction will be provided in the coming weeks as the Company works to conclude its strategic review of its assets. The purpose is to fully reflect the value of the different assets. Andrew DeFrancesco will lead the newly formed SOL Investment Group (SIG) and step down from his roles as Chairman & CIO of SOL Global.

SOL Global to focus on the US states of Florida, Michigan and California and on being more profitable

Initial operations for SOL Global will include assets in three of the top ten cannabis revenue markets in the U.S; namely Florida, Michigan and California. The new Company strategy is also to be more profitable by keeping the capital and operating expenses low with an efficiency-driven model of integrating operations and streamlining.

The timing of the proposed change of business is strategic, as SOL Global CEO Brady Cobb commented: “One of the innate strengths of SOL Global’s management is knowing when to enter a market, as is evidenced with our early success in Canada and Florida. We have planned this transition and the market entrance of our MSO to coincide with the rapid growth of the legal U.S. cannabis marketplace amid a presumptive tail wind from federal policy reform initiatives related to cannabis.”

Bluma Wellness – Everyone to “bloom”

The Company’s proposed change of name to Bluma Wellness Inc. was selected to ensure that patients and consumers utilizing SOL Global’s plant-based products can enhance their daily lives, namely to bloom and thrive. Bluma is an ancient Hebrew word which means to flower, bloom or blossom.

Mr. Cobb adds: “We chose the name Bluma Wellness as an appropriate way to honor the true intent of each seed that we cultivate, harvest, and deliver as a product.”

SOL plans to complete previously announced acquisitions. This will include the licensed dispensaries operated by MCP Wellness in Michigan (April 24, 2019), California based acquisitions which include the famed Humboldt, cultivator “Northern Emeralds” and dispensary chain “One Plant USA” (May 16, 2019). The resulting products of the new combined company Bluma Wellness will be powered by Northern Emeralds’ genetics cultivation and processing techniques that will be anchored by the brands and products that SOL Global has invested in. The product will then be deployed by dispensaries that include One Plant’s robust retail arm across the states of Florida, Michigan, and California.

Some of the SOL Global’s portfolio of investments 

Note: Added to above is also PRØHBTD, which is a media platform built exclusively to create, develop and market cannabis brands to global audiences. Also a ~42% stake in Heavenly Rx Ltd, and an alliance with the University of Miami.

Despite market volatility, SOL Global is holding to its strategic direction and has continued to make additional investments in the cannabis, CBD and hemp sectors. The Company’s renewed focus is on the key US states of Michigan, California, and Florida. SOL is also investing in operational upgrades to efficiently scale up operations to expedite the path to profitability for the newly named Bluma Wellness, which they expect will ultimately deliver value to shareholders. SOL Global certainly has firm plans to bloom in a new name, and now a whole new structure.

SOL Global Investments Corp. is headquartered in Toronto Canada; and has a market cap of C$ 70 million.

StageZero’s James Howard-Tripp on diagnosing cancer early

“We are all about finding diseases early. Our current focus is on cancer. If you can find it early your survival is greatest, your costs are lower. That’s what it is all about.” States James Howard-Tripp, Chairman and CEO of StageZero Life Sciences, Ltd. (TSX: SZLS), in an interview with InvestorIntel’s Tracy Weslosky.

James went on to provide an update on StageZero’s collaboration with Coastal Medical (to increase outreach to physician practices and hospital systems throughout the Southeast). James said that they have fully trained the Salesforce and the Coastal Medical team is in the field. James also provided an update on StageZero’s recent private placement. He said that the private placement was fully subscribed and the company has raised $3.7 million. He further added that StageZero is expected to breakeven before year-end. The company is starting to ramp up and is expecting good growth in sales and revenue.

To access the complete interview, click here

Disclaimer: StageZero Life Sciences, Ltd. is an advertorial member of InvestorIntel Corp.

Skin cancer technology company wins #1 for audience favorite at the ii6 Summit

Letter from the Publisher: We recently hosted the ii6 Summit Series – V01 at the King Edward in Toronto and had 6 companies present to an InvestorIntel audience of just over 3-dozen people, our next one is Thursday, September 5th. The #1 favorite company, according to those that we surveyed was MedX Health Corp., so we had Matt Bohlsen provide us with an update on this skin cancer technology company.

MedX Health Corp. (TSXV: MDX) is a leading medical device and software company focused on developing and implementing non-invasive, practical, drug-free and cost-effective skin analysis and assessment systems (focused on skin cancers). The Company sells its SIAscopy technology (device) and DermSecure™ telemedicine platform. Additionally, MedX designs, manufactures and distributes quality photobiomodulation devices (lasers) often used for pain management and wound healing, especially in dentistry or where there is tissue damage (ulcers, etc).

SIAscopy device and the DermSecure™ telemedicine platform

Physicians can more accurately evaluate suspicious moles and lesions in a non-invasive, pain-free way by using the SIAscopy skin screening procedure for moles and lesions. By utilizing light, the handheld SIAscopy device can view up to 2 mm beneath suspicious moles and lesions. The DermSecure™ telemedicine platform can then create software enabled real-time images for trained medical professionals to view within seconds, anywhere in the world that is connected online. If you have a suspicious mole or lesion MedX’s technology can reduce wait times to see a dermatologist from up to 16 months down to as little as 72 hours.

MedX health’s SIAscopy device can see up to 2mm beneath the skin

Patients suffering from mucositis or oral ulcerations from head and neck cancer radiation treatment can now be effectively treated with MedX’s light therapy devices

Following the announcement of new guidelines from the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology, patients suffering oral ulcerations (and mucositis) caused by head and neck cancer radiation treatment can now be effectively treated with MedX’s light therapy devices. A coalition of researchers and clinicians worldwide have agreed light therapy is among the most effective interventions for the prevention of painful oral ulcers in the mouth and throat resulting from cancer therapy.

Scott Spearn, CEO of MedX noted: “With these new guidelines we expect our devices will help dramatically reduce mucositis.”

The point of this is MedX products are effective and pain free. The Company’s products have been on the market for other conditions, and are FDA cleared and Health Canada licensed for photobiomodulation (PBM) light therapy.  MedX’s PBM devices are now already being used in a number of mucositis treatment studies in Canada and the US.

MedX Health’s Photobiomodulation (PBM) light therapy device helps pain and healing

This will represent a significant sales opportunity in Canada and the United States for MedX’s PBM light therapy devices where more than 70,000 head and neck cancers are diagnosed annually. It has been documented that 100% of patients undergoing radiation therapy for these cancers will develop painful oral ulcers, of which many patients report as the worst side effect of their cancer treatment. MedX is expecting sales of their PBM therapy products to accelerate over the following year as they focus on rolling out a marketing campaign within this segment across North America.

Dr. Praveen Arany the President of the World Association for PBM therapy said: “Cancer patients can now benefit from this non-invasive, non-pharmacological treatment for a common, debilitating side effect of treatment. Recent advancements in our understanding of mechanisms of low dose light treatments are enabling rigorous validation of clinical protocols.”

MedX Health also designs, manufactures and distributes quality dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, and Turkey.

Update on distribution agreement to Launch DermSecure™ in Brazil

MedX is now getting closer to final regulatory approval in Brazil which will give the Company access to a 212 million population base, where unfortunately malignant melanoma is often not detected until the later stages. As a reminder, there were over 100,000 cases of skin cancer diagnosed in Brazil between 2016 and 2017, and almost 6,000 were melanomas.

MedX Health Corp. is headquartered in Mississauga, Ontario, Canada; and has a market cap of C$ 16.8 million.